Nanopath has raised $25 million in Series B funding to support an FDA 510(k) study and scale-up of its 15-minute point-of-care vaginitis assay, with participation from Norwest, SV Health Investors, and Labcorp Venture Fund.
New England Biolabs will present new multiomic cell-free DNA and RNA analysis workflows, including enzymatic methylation profiling, at AMP 2026, with details on integrated protocols for molecular diagnostics.
Toumy Guettouche, PhD, chief scientific officer at Mercy BioAnalytics and a study co-author, discusses how a blood test measuring proteins on extracellular vesicles detected signs of early-stage ovarian cancer before diagnosis—and what researchers still need to establish before the approach could be used for routine screening.
The new platform offers custom panel manufacturing in as little as one day to support development of tumor-informed MRD assays.
The FDA has cleared Cepheid’s Xpert Hemorrhagic Fever Panel, a multiplex PCR test that detects four hemorrhagic fever viruses and delivers results in about an hour on GeneXpert Dx systems, according to the company.
Contrario Medical's single-use device uses a two-membrane design to prepare motile sperm from semen samples.
The molecular test could help identify patients more likely to respond to abatacept, with early access expected in 2027.
Researchers developed a simplified metabolic health score using routine blood markers to identify people at greater risk of developing cardiometabolic disease.
The patent expands intellectual property coverage for the blood-based assay ahead of its planned commercial launch.
Screen retention errors can misassign patient glucose results in electronic records, leading to one reported injury and a planned software update.
A study of more than 1,100 transplant recipients found that persistent or later-emerging elevations in donor-derived cell-free DNA were associated with greater risks of rejection and graft loss.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
Tampa General Hospital is the first in the Southeast to implement the MeMed BV host-response test in its emergency workflow, reporting a 33% reduction in cefepime use and 13% fewer hospitalizations, according to hospital-led research.